Haleon (HLN) posts Q3 trading update; investor call details
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Haleon plc filed a Form 6-K announcing its Q3 2025 trading statement is available online, including on its investor site and via the UK FCA’s National Storage Mechanism.
The Company will host a short presentation and Q&A at 9:00am GMT (10:00am CET) on 30 October 2025, led by Chief Financial Officer Dawn Allen, with access via www.haleon.com/investors.
Dial-in details include UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228. An archived webcast will be available later the same day.
Positive
- None.
Negative
- None.
FAQ
Where can I access Haleon (HLN) Q3 2025 trading statement?
The statement is available at www.haleon.com/investors and via the FCA’s National Storage Mechanism; a specific RNS PDF link is provided.
When is Haleon’s Q3 2025 investor presentation and Q&A?
The session is scheduled for 9:00am GMT (10:00am CET) on 30 October 2025.
Who will host Haleon’s Q3 2025 presentation?
The presentation and Q&A will be hosted by Chief Financial Officer Dawn Allen.
How do I dial in to Haleon’s Q3 2025 Q&A call?
UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228.
Will a replay of Haleon’s Q3 2025 call be available?
Yes. An archived webcast of the Q&A will be available later the same day at www.haleon.com/investors.
What are Haleon’s tickers and business focus?
Haleon trades as LSE/NYSE: HLN and is a global consumer health company with brands such as Sensodyne, Panadol, and Voltaren.
How can I contact Haleon’s investor relations team?
Email investor-relations@haleon.com; investor contacts include Jo Russell and Rakesh Patel.
